Reduction of lipoprotein(a) with proprotein convertase subtilisin/kexin type 9 inhibitor as a potential contributor to modulating coronary inflammatory activity: insights from serial pericoronary adipose tissue analysis

被引：2
|
作者：
Kitahara, Satoshi [1 ]
Kataoka, Yu [1 ]
Miura, Hiroyuki [1 ]
Noguchi, Teruo [1 ]
机构：
[1] Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan
来源：
EUROPEAN HEART JOURNAL | 2022年 / 43卷 / 16期
关键词：
D O I：
10.1093/eurheartj/ehab882
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1597 / 1597
页数：1
相关论文
共 50 条
  • [1] Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: An unsolved mystery
    Liberopoulos, Evangelos
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (08) : 813 - 815
  • [2] Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis
    Farmakis, Ioannis
    Doundoulakis, Ioannis
    Pagiantza, Areti
    Zafeiropoulos, Stefanos
    Antza, Christina
    Karvounis, Haralambos
    Giannakoulas, George
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (03) : 397 - 407
  • [3] Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Lipid Reduction: A Network Meta-Analysis
    Shen, Hua
    Chai, Meng
    Zhou, Yujie
    CIRCULATION, 2024, 150
  • [4] Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Oxidized Lipoprotein Levels: A Case Report
    Kotani, Kazuhiko
    Sakane, Naoki
    JOURNAL OF APPLIED LABORATORY MEDICINE, 2020, 5 (05): : 1124 - 1126
  • [5] Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Treatment for Repeated In-stent Restenosis in a Coronary Artery
    Akiyama, Takumi
    Ozaki, Kazuyuki
    Takano, Toshiki
    Yoneyama, Shintaro
    Kubota, Naoki
    Okubo, Takeshi
    Ikegami, Ryutaro
    Hoyano, Makoto
    Yanagawa, Takao
    Inomata, Takayuki
    INTERNAL MEDICINE, 2023, 62 (22) : 3361 - 3365
  • [6] Effects of a Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitor, Alirocumab, on Lipid and Lipoprotein Metabolism in Healthy Subjects
    Reyes-Soffer, Gissette
    Pavlyha, Marianna
    Ngai, Colleen
    Thomas, Tiffany
    Holleran, Stephen
    Ramakrishnan, Sekhar
    Karmally, Wahida
    Donovan, Daniel
    Cowan, Lisa
    Sasiela, William
    Surks, Howard
    Rey, Jacques
    Poitiers, Frank
    Ginsberg, Henry
    CIRCULATION, 2015, 132
  • [7] Proprotein convertase subtilisin/kexin type 9 inhibitor non responses in an adult with a history of coronary revascularization: A case report
    Liu Yang
    Yan-Yan Xiao
    Liang Shao
    Chang-Sheng Ouyang
    Yao Hu
    Bin Li
    Li-Feng Lei
    Hong Wang
    World Journal of Clinical Cases, 2022, 10 (19) : 6728 - 6735
  • [8] Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways
    Cameron, Jamie
    Bogsrud, Martin P.
    Tveten, Kristian
    Strom, Thea Bismo
    Holven, Kirsten
    Berge, Knut Erik
    Leren, Trond P.
    TRANSLATIONAL RESEARCH, 2012, 160 (02) : 125 - 130
  • [9] Proprotein convertase subtilisin/kexin type 9 inhibitor non responses in an adult with a history of coronary revascularization: A case report
    Yang, Liu
    Xiao, Yan-Yan
    Shao, Liang
    Ouyang, Chang-Sheng
    Hu, Yao
    Li, Bin
    Lei, Li-Feng
    Wang, Hong
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (19) : 6728 - 6735
  • [10] Plasma eicosanoid profiling in the course of proprotein convertase Subtilisin-Kexin type 9 inhibition: Insights from a metabolomic analysis
    Schrutka, L.
    Hagn, G.
    Galli, L.
    Poeschl, A.
    Seidl, V
    Ondracek, A. S.
    Bileck, A.
    Lang, I
    Hengstenberg, C.
    Krychtiuk, K.
    Speidl, W.
    Gerner, C.
    Distelmaier, K.
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (SUPPL 2) : 160 - 161
12345